Eli Lilly and Company (NYSE:LLY) Trading Up 1.6%

Eli Lilly and Company (NYSE:LLY)’s share price shot up 1.6% during trading on Monday . The stock traded as high as $768.00 and last traded at $763.53. 810,891 shares traded hands during trading, a decline of 74% from the average session volume of 3,070,517 shares. The stock had previously closed at $751.64.

Analyst Ratings Changes

A number of brokerages have weighed in on LLY. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Barclays lifted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The business has a 50-day moving average price of $763.51 and a 200-day moving average price of $657.01. The firm has a market capitalization of $709.35 billion, a price-to-earnings ratio of 128.72, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the firm earned $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Hedge funds have recently bought and sold shares of the business. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Tidemark LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Finally, Retirement Group LLC boosted its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.